Evaluation of Different Surface Coating Agents for Selenium Nanoparticles: Enhanced Anti-Inflammatory Activity and Drug Loading Capacity.
carrageenan
indomethacin
polyethylene glycol
selenium nanoparticles
soybean lecithin
synergistic activity
β-cyclodextrin
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
02
2022
accepted:
28
05
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
22
6
2022
Statut:
epublish
Résumé
Inflammation is the keystone in the disease's pathological process in response to any damaging stimuli. Therefore, any agent that inhibits the inflammatory response is under focus, either a drug or a bioactive compound. Selenium nanoparticles have drawn attention in various biomedical applications, including the anti-inflammatory activity. In the current study, we aimed to evaluate the capacity of different surface coating materials (soybean lecithin, PEG 6000, and β-cyclodextrin) to enhance the anti-inflammatory activity of the synthesized selenium nanoparticles (SeNPs). The capability of the coated SeNPs to adsorb indomethacin (IND) on their surfaces compared to the uncoated SeNPs was also evaluated. SeNPs were synthesized, coated with different materials, and characterized in vitro using X-ray diffraction, UV-Vis spectrophotometer, FTIR, SEM, TEM, and particle size and zeta potential measurements. The in vivo anti-inflammatory activity of the uncoated/coated SeNPs loaded into hydrogel was evaluated using a carrageenan-induced paw edema rat model. The effect of SeNPs surface coatings was further evaluated for IND loading capacity. Our findings proved the superior anti-inflammatory activity of all coated SeNPs compared to the uncoated SeNPs, especially with β-cyclodextrin surface coating. Regarding the IND loading capacity of the prepared uncoated/coated SeNPs, the amount of drug loaded was 0.12, 1.12, 0.3, and 0.14 µg IND/µg SeNPs for the uncoated, lecithin-, PEG- and β-CD-coated SeNPs, respectively. Surface functionalization of SeNPs can provide a synergistic therapeutic activity. Our results are promising for further investigation of the in vivo anti-inflammatory synergistic activity of the IND-loaded surface-coated SeNPs.
Sections du résumé
Background
UNASSIGNED
Inflammation is the keystone in the disease's pathological process in response to any damaging stimuli. Therefore, any agent that inhibits the inflammatory response is under focus, either a drug or a bioactive compound. Selenium nanoparticles have drawn attention in various biomedical applications, including the anti-inflammatory activity.
Purpose
UNASSIGNED
In the current study, we aimed to evaluate the capacity of different surface coating materials (soybean lecithin, PEG 6000, and β-cyclodextrin) to enhance the anti-inflammatory activity of the synthesized selenium nanoparticles (SeNPs). The capability of the coated SeNPs to adsorb indomethacin (IND) on their surfaces compared to the uncoated SeNPs was also evaluated.
Methods
UNASSIGNED
SeNPs were synthesized, coated with different materials, and characterized in vitro using X-ray diffraction, UV-Vis spectrophotometer, FTIR, SEM, TEM, and particle size and zeta potential measurements. The in vivo anti-inflammatory activity of the uncoated/coated SeNPs loaded into hydrogel was evaluated using a carrageenan-induced paw edema rat model. The effect of SeNPs surface coatings was further evaluated for IND loading capacity.
Results
UNASSIGNED
Our findings proved the superior anti-inflammatory activity of all coated SeNPs compared to the uncoated SeNPs, especially with β-cyclodextrin surface coating. Regarding the IND loading capacity of the prepared uncoated/coated SeNPs, the amount of drug loaded was 0.12, 1.12, 0.3, and 0.14 µg IND/µg SeNPs for the uncoated, lecithin-, PEG- and β-CD-coated SeNPs, respectively.
Conclusion
UNASSIGNED
Surface functionalization of SeNPs can provide a synergistic therapeutic activity. Our results are promising for further investigation of the in vivo anti-inflammatory synergistic activity of the IND-loaded surface-coated SeNPs.
Identifiants
pubmed: 35719212
doi: 10.2147/DDDT.S360344
pii: 360344
pmc: PMC9205440
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Lecithins
0
beta-Cyclodextrins
0
Selenium
H6241UJ22B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1811-1825Informations de copyright
© 2022 Mekkawy et al.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Nanobiotechnology. 2017 Jan 5;15(1):4
pubmed: 28056992
Hum Exp Toxicol. 2019 Apr;38(4):398-408
pubmed: 30526071
Br J Nutr. 2012 Nov 28;108(10):1829-38
pubmed: 22273003
J Microencapsul. 2011;28(8):807-15
pubmed: 22117177
Curr Pharm Des. 2017;23(14):2096-2107
pubmed: 28128055
Int J Pharm. 2021 Mar 15;597:120287
pubmed: 33524523
Mutat Res. 1997 May 23;390(3):201-5
pubmed: 9186569
J Cosmet Sci. 2013 Sep-Oct;64(5):341-53
pubmed: 24139433
Biofactors. 2001;15(1):27-38
pubmed: 11673642
J Toxicol Clin Toxicol. 1999;37(2):145-72
pubmed: 10382553
Can J Physiol Pharmacol. 2017 Feb;95(2):101-110
pubmed: 27936913
Nanomaterials (Basel). 2017 Dec 27;8(1):
pubmed: 29280980
Adv Healthc Mater. 2021 Aug;10(16):e2100598
pubmed: 34121366
J Biomed Mater Res B Appl Biomater. 2016 Jul;104(5):993-1003
pubmed: 25994972
Nano Converg. 2020 Apr 23;7(1):14
pubmed: 32328852
J Inorg Biochem. 2007 Oct;101(10):1457-63
pubmed: 17664013
Acta Biomater. 2015 Oct;25:172-83
pubmed: 26143603
Int J Nanomedicine. 2020 Jan 08;15:115-124
pubmed: 32021168
IET Nanobiotechnol. 2014 Dec;8(4):282-9
pubmed: 25429509
J Nanosci Nanotechnol. 2015 Dec;15(12):10165-72
pubmed: 26682463
Clin Ther. 2012 Sep;34(9):1954-63
pubmed: 22939163
Front Microbiol. 2019 Apr 30;10:931
pubmed: 31114564
J Mater Chem B. 2017 Dec 28;5(48):9452-9476
pubmed: 32264560
Food Chem Toxicol. 2020 Oct;144:111621
pubmed: 32738372
Drug Dev Ind Pharm. 2004 Mar;30(3):303-17
pubmed: 15109030
Sci Rep. 2019 Apr 15;9(1):6044
pubmed: 30988361
Biomed Res Int. 2018 Jul 9;2018:3785487
pubmed: 30112384
J Biomed Mater Res. 1972 Nov;6(6):571-82
pubmed: 4642986
Sci Total Environ. 2008 Aug 1;400(1-3):115-41
pubmed: 18657851
Front Microbiol. 2019 Jul 26;10:1632
pubmed: 31402902
Biomolecules. 2019 Jun 21;9(6):
pubmed: 31234312
Nanomaterials (Basel). 2021 Aug 05;11(8):
pubmed: 34443836
AAPS PharmSciTech. 2008;9(2):563-70
pubmed: 18459056
Crit Care Med. 2010 Feb;38(2):629-36
pubmed: 20009757
Cochrane Database Syst Rev. 2010 Jun 16;(6):CD007402
pubmed: 20556778
J Liposome Res. 2010 Dec;20(4):323-9
pubmed: 20131982
Methods Mol Biol. 2003;225:115-21
pubmed: 12769480
Mater Today Commun. 2018 Dec;17:200-213
pubmed: 32289062
Artif Cells Nanomed Biotechnol. 2021 Dec;49(1):48-60
pubmed: 33403879
Biomolecules. 2021 Sep 19;11(9):
pubmed: 34572597
Int J Nanomedicine. 2013;8:1713-20
pubmed: 23658489
Biomaterials. 2013 Sep;34(29):7106-16
pubmed: 23800743
Int J Mol Sci. 2016 Jun 30;17(7):
pubmed: 27376279
Molecules. 2020 Aug 06;25(16):
pubmed: 32781622
Chem Commun (Camb). 2018 Aug 2;54(63):8753-8756
pubmed: 30028456
Food Chem Toxicol. 2014 Jun;68:183-9
pubmed: 24626144
Biofactors. 2010 May-Jun;36(3):210-5
pubmed: 20336709
Front Bioeng Biotechnol. 2021 Jan 25;8:624621
pubmed: 33569376
AAPS PharmSciTech. 2021 Dec 20;23(1):29
pubmed: 34931279
Int J Nanomedicine. 2020 Jun 17;15:4275-4288
pubmed: 32606677
Exp Anim. 2009 Jul;58(4):431-6
pubmed: 19654443
Circulation. 2002 Mar 5;105(9):1135-43
pubmed: 11877368
Int J Nanomedicine. 2017 Jan 23;12:759-777
pubmed: 28176951
Nanomaterials (Basel). 2021 Sep 18;11(9):
pubmed: 34578754
Int J Nanomedicine. 2013;8:4399-413
pubmed: 24265551
Inflammation. 1994 Jun;18(3):285-92
pubmed: 7522223
J Nanobiotechnology. 2021 Apr 13;19(1):101
pubmed: 33849555
Int J Mol Sci. 2021 Oct 28;22(21):
pubmed: 34769138
Biochem Biophys Res Commun. 2019 Oct 1;517(4):684-690
pubmed: 31400855
J Biochem Mol Toxicol. 2022 Apr;36(4):e22989
pubmed: 35179263